Royal Philips Acquires CardioProlific

 

June 29, 2017—Royal Philips announced the acquisition of CardioProlific Inc., which is developing catheter-based thrombectomy approaches to treat peripheral vascular disease. Financial details of the transaction will not be disclosed. CardioProlific is a privately held company based in California.

According to Philips, CardioProlific’s technologies are complementary to the company's portfolio of image-guided therapy devices and to the portfolio of Spectranetrics Corporation, which Philips recently announced it would acquire.

The development of CardioProlific’s differentiated thrombectomy technologies will combine with Philip's suite of image-guided therapy solutions to address the treatment of peripheral vascular disease. Philips’ image-guided therapy portfolio includes interventional imaging systems, planning and navigation software, interventional devices (both diagnostic and therapeutic catheters), and a range of services.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.